VERICEL CORPORATION Finite-Lived Intangible Assets, Net
VERICEL CORPORATION (VCEL) had Finite-Lived Intangible Assets, Net of $5.31 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-07-30
- 2026-06-30: Finite-Lived Intangible Assets, Net $5.31M.
- 2026-03-31: Finite-Lived Intangible Assets, Net $5.47M.
- 2025-12-31: Finite-Lived Intangible Assets, Net $5.63M.
- 2025-09-30: Finite-Lived Intangible Assets, Net $5.78M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2026-06-30 | $5.31M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $5.47M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $5.63M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $5.78M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.94M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $6.09M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $6.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.41M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $6.56M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $6.72M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $6.88M 10-K · filed 2025-02-27 |
| 2023-09-30 | $7.03M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $7.19M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $7.34M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $7.50M 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2016-09-30 | $2.71M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $2.78M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $2.85M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $2.92M 10-K · filed 2016-03-14 |
| 2015-09-30 | $2.99M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $3.06M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $3.13M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $3.20M 10-K · filed 2015-03-25 |
| 2014-09-30 | $3.27M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $3.36M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |